Furthermore, when diabetic patients with CKD require additional treatment for glycemic control, or cannot use metformin and/or SGLT2 inhibitors, the KDIGO guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RA) as the preferred option, due to the cardiovascular and renal benefit they have proven in the recent trials [42,43,44,45,46]. The gene discussed is SLC5A2; the disease is chronic kidney disease.